ChromaDex: Difference between revisions
Tags: Reverted Visual edit: Switched |
LilianaUwU (talk | contribs) Reverted 3 edits by Health.Science.24 (talk): Bunch of spam |
||
Line 14: | Line 14: | ||
'''ChromaDex''' is a [[dietary supplement]] and [[food ingredient]] company based in [[Los Angeles, California]] founded in 1999 that is publicly traded on the NASDAQ. |
'''ChromaDex''' is a [[dietary supplement]] and [[food ingredient]] company based in [[Los Angeles, California]] founded in 1999 that is publicly traded on the NASDAQ. |
||
In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis |
In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen and sells directly to consumers as Tru Niagen.<ref name="deathmatch">{{cite web|url=https://medium.com/neodotlife/elysium-and-basis-vs-chromadex-and-tru-niagen-10264fca0bdb|last1=Weintraub|first1=Karen|title=The Life Extension Death Match|work=NEO.LIFE}}</ref> ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |work= |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref> |
||
[[Elysium Health]] bought the ingredients in its "Basis" product from ChromaDex.<ref name=Wired>{{cite news|last1=Zhang|first1=Sarah|title=The Weird Business Behind a Trendy "Anti-Aging" Pill|url=https://www.wired.com/2016/07/confused-elysiums-anti-aging-drug-yeah-fda/|work=Wired|date=July 6, 2016}}</ref> The two firms had an agreement under which Elysium didn't have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the VP of business development from ChromaDex and stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.<ref name=TC>{{cite news|last1=Buhr|first1=Sarah|title=A new lawsuit alleges anti-aging startup Elysium Health hasn’t paid its sole supplier|url=https://techcrunch.com/2017/01/16/a-new-lawsuit-alleges-anti-aging-startup-elysium-health-hasnt-paid-its-supplier-and-is-in-breach-of-agreement/|work=TechCrunch|date=January 16, 2017}}</ref> |
|||
ChromaDex also licensed patents from the University of Mississippi on Immulina, a proprietary extract of ''Arthrospira platensis'' (or spirulina, a type of algae) which it continues to sell today as an ingredient for use in dietary supplements. |
|||
== History == |
|||
Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on NR in 2012, leading to the commercialization of Niagen in 2013. |
|||
ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018. |
|||
In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone NR supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million, led by Horizons Ventures, the investment firm of Hong Kong billionaire Li Ka-Shing, as well as venture capitalists and strategic investors, including ICONIQ Capital, to support research and development, and global expansion. |
|||
== Niagen NR Clinical Studies == |
|||
Niagen, the active ingredient in Tru Niagen, is the only patented form of NR that has been extensively studied in published human clinical trials <ref>{{Cite journal |last=Trammell |first=Samuel A. J. |last2=Schmidt |first2=Mark S. |last3=Weidemann |first3=Benjamin J. |last4=Redpath |first4=Philip |last5=Jaksch |first5=Frank |last6=Dellinger |first6=Ryan W. |last7=Li |first7=Zhonggang |last8=Abel |first8=E. Dale |last9=Migaud |first9=Marie E. |last10=Brenner |first10=Charles |date=2016-10-10 |title=Nicotinamide riboside is uniquely and orally bioavailable in mice and humans |url=https://www.nature.com/articles/ncomms12948 |journal=Nature Communications |language=en |volume=7 |issue=1 |pages=12948 |doi=10.1038/ncomms12948 |issn=2041-1723 |pmc=PMC5062546 |pmid=27721479}}</ref><ref>{{Cite journal |last=Airhart |first=Sophia E. |last2=Shireman |first2=Laura M. |last3=Risler |first3=Linda J. |last4=Anderson |first4=Gail D. |last5=Gowda |first5=G. A. Nagana |last6=Raftery |first6=Daniel |last7=Tian |first7=Rong |last8=Shen |first8=Danny D. |last9=O’Brien |first9=Kevin D. |date=2017-12-06 |title=An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers |url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186459 |journal=PLOS ONE |language=en |volume=12 |issue=12 |pages=e0186459 |doi=10.1371/journal.pone.0186459 |issn=1932-6203 |pmc=PMC5718430 |pmid=29211728}}</ref><ref>{{Cite journal |last=Martens |first=Christopher R. |last2=Denman |first2=Blair A. |last3=Mazzo |first3=Melissa R. |last4=Armstrong |first4=Michael L. |last5=Reisdorph |first5=Nichole |last6=McQueen |first6=Matthew B. |last7=Chonchol |first7=Michel |last8=Seals |first8=Douglas R. |date=2018-03-29 |title=Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults |url=https://www.nature.com/articles/s41467-018-03421-7 |journal=Nature Communications |language=en |volume=9 |issue=1 |pages=1286 |doi=10.1038/s41467-018-03421-7 |issn=2041-1723 |pmc=PMC5876407 |pmid=29599478}}</ref><ref>{{Cite journal |last=Dollerup |first=Ole L |last2=Christensen |first2=Britt |last3=Svart |first3=Mads |last4=Schmidt |first4=Mark S |last5=Sulek |first5=Karolina |last6=Ringgaard |first6=Steffen |last7=Stødkilde-Jørgensen |first7=Hans |last8=Møller |first8=Niels |last9=Brenner |first9=Charles |last10=Treebak |first10=Jonas T |last11=Jessen |first11=Niels |date=2018-08-01 |title=A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects |url=https://www.sciencedirect.com/science/article/pii/S0002916522029409 |journal=The American Journal of Clinical Nutrition |language=en |volume=108 |issue=2 |pages=343–353 |doi=10.1093/ajcn/nqy132 |issn=0002-9165}}</ref><ref>{{Cite journal |last=Conze |first=Dietrich |last2=Brenner |first2=Charles |last3=Kruger |first3=Claire L. |date=2019-07-05 |title=Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults |url=https://www.nature.com/articles/s41598-019-46120-z |journal=Scientific Reports |language=en |volume=9 |issue=1 |pages=9772 |doi=10.1038/s41598-019-46120-z |issn=2045-2322 |pmc=PMC6611812 |pmid=31278280}}</ref><ref>{{Cite journal |last=Elhassan |first=Yasir S. |last2=Kluckova |first2=Katarina |last3=Fletcher |first3=Rachel S. |last4=Schmidt |first4=Mark S. |last5=Garten |first5=Antje |last6=Doig |first6=Craig L. |last7=Cartwright |first7=David M. |last8=Oakey |first8=Lucy |last9=Burley |first9=Claire V. |last10=Jenkinson |first10=Ned |last11=Wilson |first11=Martin |last12=Lucas |first12=Samuel J. E. |last13=Akerman |first13=Ildem |last14=Seabright |first14=Alex |last15=Lai |first15=Yu-Chiang |date=2019-08-13 |title=Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures |url=https://www.cell.com/cell-reports/abstract/S2211-1247(19)30940-4 |journal=Cell Reports |language=English |volume=28 |issue=7 |pages=1717–1728.e6 |doi=10.1016/j.celrep.2019.07.043 |issn=2211-1247 |pmc=PMC6702140 |pmid=31412242}}</ref><ref>{{Cite journal |last=Dollerup |first=Ole L |last2=Trammell |first2=Samuel A J |last3=Hartmann |first3=Bolette |last4=Holst |first4=Jens J |last5=Christensen |first5=Britt |last6=Møller |first6=Niels |last7=Gillum |first7=Matthew P |last8=Treebak |first8=Jonas T |last9=Jessen |first9=Niels |date=2019-11-01 |title=Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity |url=https://academic.oup.com/jcem/article/104/11/5703/5544497 |journal=The Journal of Clinical Endocrinology & Metabolism |language=en |volume=104 |issue=11 |pages=5703–5714 |doi=10.1210/jc.2019-01081 |issn=0021-972X}}</ref><ref>{{Cite journal |last=Dollerup |first=Ole L. |last2=Chubanava |first2=Sabina |last3=Agerholm |first3=Marianne |last4=Søndergård |first4=Stine D. |last5=Altıntaş |first5=Ali |last6=Møller |first6=Andreas B. |last7=Høyer |first7=Kasper F. |last8=Ringgaard |first8=Steffen |last9=Stødkilde‐Jørgensen |first9=Hans |last10=Lavery |first10=Gareth G. |last11=Barrès |first11=Romain |last12=Larsen |first12=Steen |last13=Prats |first13=Clara |last14=Jessen |first14=Niels |last15=Treebak |first15=Jonas T. |date=2020-02 |title=Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin‐resistant men |url=https://onlinelibrary.wiley.com/doi/10.1113/JP278752 |journal=The Journal of Physiology |language=en |volume=598 |issue=4 |pages=731–754 |doi=10.1113/JP278752 |issn=0022-3751}}</ref><ref>{{Cite journal |last=Remie |first=Carlijn ME |last2=Roumans |first2=Kay HM |last3=Moonen |first3=Michiel PB |last4=Connell |first4=Niels J |last5=Havekes |first5=Bas |last6=Mevenkamp |first6=Julian |last7=Lindeboom |first7=Lucas |last8=de Wit |first8=Vera HW |last9=van de Weijer |first9=Tineke |last10=Aarts |first10=Suzanne ABM |last11=Lutgens |first11=Esther |last12=Schomakers |first12=Bauke V |last13=Elfrink |first13=Hyung L |last14=Zapata-Pérez |first14=Rubén |last15=Houtkooper |first15=Riekelt H |date=2020-08-01 |title=Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans |url=https://www.sciencedirect.com/science/article/pii/S0002916522008103 |journal=The American Journal of Clinical Nutrition |language=en |volume=112 |issue=2 |pages=413–426 |doi=10.1093/ajcn/nqaa072 |issn=0002-9165 |pmc=PMC7398770 |pmid=32320006}}</ref><ref>{{Cite journal |last=Zhang |first=Cheng |last2=Bjornson |first2=Elias |last3=Arif |first3=Muhammad |last4=Tebani |first4=Abdellah |last5=Lovric |first5=Alen |last6=Benfeitas |first6=Rui |last7=Ozcan |first7=Mehmet |last8=Juszczak |first8=Kajetan |last9=Kim |first9=Woonghee |last10=Kim |first10=Jung Tae |last11=Bidkhori |first11=Gholamreza |last12=Ståhlman |first12=Marcus |last13=Bergh |first13=Per‐Olof |last14=Adiels |first14=Martin |last15=Turkez |first15=Hasan |date=2020-04 |title=The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease |url=https://onlinelibrary.wiley.com/doi/10.15252/msb.209495 |journal=Molecular Systems Biology |language=en |volume=16 |issue=4 |doi=10.15252/msb.209495 |issn=1744-4292 |pmc=PMC7184219 |pmid=32337855}}</ref><ref>{{Cite journal |last=Zhou |first=Bo |last2=Wang |first2=Dennis Ding-Hwa |last3=Qiu |first3=Yanhua |last4=Airhart |first4=Sophia |last5=Liu |first5=Yaxin |last6=Stempien-Otero |first6=April |last7=O’Brien |first7=Kevin D. |last8=Tian |first8=Rong |date=2020-11-02 |title=Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure |url=https://www.jci.org/articles/view/138538 |journal=The Journal of Clinical Investigation |language=en |volume=130 |issue=11 |pages=6054–6063 |doi=10.1172/JCI138538 |issn=0021-9738 |pmc=PMC7598081 |pmid=32790648}}</ref><ref>{{Cite journal |last=Tinnevelt |first=Gerjen H. |last2=Engelke |first2=Udo F. H. |last3=Wevers |first3=Ron A. |last4=Veenhuis |first4=Stefanie |last5=Willemsen |first5=Michel A. |last6=Coene |first6=Karlien L. M. |last7=Kulkarni |first7=Purva |last8=Jansen |first8=Jeroen J. |date=2020-11 |title=Variable Selection in Untargeted Metabolomics and the Danger of Sparsity |url=https://www.mdpi.com/2218-1989/10/11/470 |journal=Metabolites |language=en |volume=10 |issue=11 |pages=470 |doi=10.3390/metabo10110470 |issn=2218-1989 |pmc=PMC7698561 |pmid=33213095}}</ref><ref>{{Cite journal |last=Stocks |first=Ben |last2=Ashcroft |first2=Stephen P. |last3=Joanisse |first3=Sophie |last4=Elhassan |first4=Yasir S. |last5=Lavery |first5=Gareth G. |last6=Dansereau |first6=Linda C. |last7=Philp |first7=Ashleigh M. |last8=Wallis |first8=Gareth A. |last9=Philp |first9=Andrew |date=2020-06-26 |title=Nicotinamide Riboside supplementation does not alter whole-body or skeletal muscle metabolic responses to a single bout of endurance exercise |url=http://biorxiv.org/lookup/doi/10.1101/2020.06.23.143446 |journal=The Journal of Physiology |language=en |doi=10.1101/2020.06.23.143446}}</ref><ref>{{Cite journal |last=Li |first=Dong-Jie |last2=Sun |first2=Si-Jia |last3=Fu |first3=Jiang-Tao |last4=Ouyang |first4=Shen-Xi |last5=Zhao |first5=Qin-Jie |last6=Su |first6=Li |last7=Ji |first7=Qing-Xi |last8=Sun |first8=Di-Ynag |last9=Zhu |first9=Jia-Hui |last10=Zhang |first10=Guo-Yan |last11=Ma |first11=Jia-Wei |last12=Lan |first12=Xiu-Ting |last13=Zhao |first13=Yi |last14=Tong |first14=Jie |last15=Li |first15=Guo-Qiang |date=2021-02-25 |title=NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin |url=https://www.thno.org/v11p4381.htm |journal=Theranostics |language=en |volume=11 |issue=9 |pages=4381–4402 |doi=10.7150/thno.53652 |issn=1838-7640 |pmc=PMC7977447 |pmid=33754067}}</ref><ref>{{Cite journal |last=Altay |first=Ozlem |last2=Arif |first2=Muhammad |last3=Li |first3=Xiangyu |last4=Yang |first4=Hong |last5=Aydın |first5=Mehtap |last6=Alkurt |first6=Gizem |last7=Kim |first7=Woonghee |last8=Akyol |first8=Dogukan |last9=Zhang |first9=Cheng |last10=Dinler‐Doganay |first10=Gizem |last11=Turkez |first11=Hasan |last12=Shoaie |first12=Saeed |last13=Nielsen |first13=Jens |last14=Borén |first14=Jan |last15=Olmuscelik |first15=Oktay |date= |title=Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19 |url=https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222 |journal=Advanced Science |language=en |volume=8 |issue=17 |pages=2101222 |doi=10.1002/advs.202101222 |issn=2198-3844 |pmc=PMC8420376 |pmid=34180141}}</ref><ref>{{Cite journal |last=Stocks |first=Ben |last2=Ashcroft |first2=Stephen P. |last3=Joanisse |first3=Sophie |last4=Dansereau |first4=Linda C. |last5=Koay |first5=Yen Chin |last6=Elhassan |first6=Yasir S. |last7=Lavery |first7=Gareth G. |last8=Quek |first8=Lake‐Ee |last9=O'Sullivan |first9=John F. |last10=Philp |first10=Ashleigh M. |last11=Wallis |first11=Gareth A. |last12=Philp |first12=Andrew |date= |title=Nicotinamide riboside supplementation does not alter whole‐body or skeletal muscle metabolic responses to a single bout of endurance exercise |url=https://onlinelibrary.wiley.com/doi/10.1113/JP280825 |journal=The Journal of Physiology |language=en |volume=599 |issue=5 |pages=1513–1531 |doi=10.1113/JP280825 |issn=0022-3751}}</ref><ref>{{Cite journal |last=Veenhuis |first=Stefanie J.G. |last2=Os |first2=Nienke J.H. |last3=Janssen |first3=Anjo J.W.M. |last4=Gerven |first4=Marjo H.J.C. |last5=Coene |first5=Karlien L.M. |last6=Engelke |first6=Udo. F.H. |last7=Wevers |first7=Ron A. |last8=Tinnevelt |first8=Gerjen H. |last9=Heine |first9=Rob |last10=Warrenburg |first10=Bart P.C. |last11=Weemaes |first11=Corry M.R. |last12=Roeleveld |first12=Nel |last13=Willemsen |first13=Michèl A.A.P. |date= |title=Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia |url=https://onlinelibrary.wiley.com/doi/10.1002/mds.28788 |journal=Movement Disorders |language=en |volume=36 |issue=12 |pages=2951–2957 |doi=10.1002/mds.28788 |issn=0885-3185}}</ref><ref>{{Cite journal |last=Zeybel |first=Mujdat |last2=Altay |first2=Ozlem |last3=Arif |first3=Muhammad |last4=Li |first4=Xiangyu |last5=Yang |first5=Hong |last6=Fredolini |first6=Claudia |last7=Akyildiz |first7=Murat |last8=Saglam |first8=Burcin |last9=Gonenli |first9=Mehmet Gokhan |last10=Ural |first10=Dilek |last11=Kim |first11=Woonghee |last12=Schwenk |first12=Jochen M |last13=Zhang |first13=Cheng |last14=Shoaie |first14=Saeed |last15=Nielsen |first15=Jens |date= |title=Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients |url=https://onlinelibrary.wiley.com/doi/10.15252/msb.202110459 |journal=Molecular Systems Biology |language=en |volume=17 |issue=10 |doi=10.15252/msb.202110459 |issn=1744-4292 |pmc=PMC8724764 |pmid=34694070}}</ref><ref>{{Cite journal |last=Wu |first=Jing |last2=Singh |first2=Komudi |last3=Lin |first3=Amy |last4=Meadows |first4=Allison M. |last5=Wu |first5=Kaiyuan |last6=Shing |first6=Vivian |last7=Bley |first7=Maximilian |last8=Hassanzadeh |first8=Shahin |last9=Huffstutler |first9=Rebecca D. |last10=Schmidt |first10=Mark S. |last11=Blanco |first11=Luz P. |last12=Tian |first12=Rong |last13=Brenner |first13=Charles |last14=Pirooznia |first14=Mehdi |last15=Kaplan |first15=Mariana J. |date=2022-03-01 |title=Boosting NAD+ blunts TLR4-induced type I IFN in control and systemic lupus erythematosus monocytes |url=https://www.jci.org/articles/view/139828 |journal=The Journal of Clinical Investigation |language=en |volume=132 |issue=5 |doi=10.1172/JCI139828 |issn=0021-9738 |pmc=PMC8884917 |pmid=35025762}}</ref><ref>{{Cite journal |last=Brakedal |first=Brage |last2=Dölle |first2=Christian |last3=Riemer |first3=Frank |last4=Ma |first4=Yilong |last5=Nido |first5=Gonzalo S. |last6=Skeie |first6=Geir Olve |last7=Craven |first7=Alexander R. |last8=Schwarzlmüller |first8=Thomas |last9=Brekke |first9=Njål |last10=Diab |first10=Joseph |last11=Sverkeli |first11=Lars |last12=Skjeie |first12=Vivian |last13=Varhaug |first13=Kristin |last14=Tysnes |first14=Ole-Bjørn |last15=Peng |first15=Shichun |date=2022-03-01 |title=The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease |url=https://www.cell.com/cell-metabolism/abstract/S1550-4131(22)00045-6 |journal=Cell Metabolism |language=English |volume=34 |issue=3 |pages=396–407.e6 |doi=10.1016/j.cmet.2022.02.001 |issn=1550-4131 |pmid=35235774}}</ref><ref>{{Cite journal |last=Wang |first=Dennis D. |last2=Airhart |first2=Sophia E. |last3=Zhou |first3=Bo |last4=Shireman |first4=Laura M. |last5=Jiang |first5=Siyi |last6=Melendez Rodriguez |first6=Carolina |last7=Kirkpatrick |first7=James N. |last8=Shen |first8=Danny D. |last9=Tian |first9=Rong |last10=O’Brien |first10=Kevin D. |date=2022-12-01 |title=Safety and Tolerability of Nicotinamide Riboside in Heart Failure with Reduced Ejection Fraction |url=https://www.sciencedirect.com/science/article/pii/S2452302X22002327 |journal=JACC Basic to Translational Science |language=en |volume=7 |issue=12 |pages=1183–1196 |doi=10.1016/j.jacbts.2022.06.012 |issn=2452-302X |pmc=PMC9831861 |pmid=36644285}}</ref><ref>{{Cite journal |last=Vreones |first=Michael |last2=Mustapic |first2=Maja |last3=Moaddel |first3=Ruin |last4=Pucha |first4=Krishna A. |last5=Lovett |first5=Jacqueline |last6=Seals |first6=Douglas R. |last7=Kapogiannis |first7=Dimitrios |last8=Martens |first8=Christopher R. |date= |title=Oral nicotinamide riboside raises NAD + and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin |url=https://onlinelibrary.wiley.com/doi/10.1111/acel.13754 |journal=Aging Cell |language=en |volume=22 |issue=1 |doi=10.1111/acel.13754 |issn=1474-9718 |pmc=PMC9835564 |pmid=36515353}}</ref><ref>{{Cite journal |last=Lapatto |first=Helena A. K. |last2=Kuusela |first2=Minna |last3=Heikkinen |first3=Aino |last4=Muniandy |first4=Maheswary |last5=van der Kolk |first5=Birgitta W. |last6=Gopalakrishnan |first6=Swetha |last7=Pöllänen |first7=Noora |last8=Sandvik |first8=Martin |last9=Schmidt |first9=Mark S. |last10=Heinonen |first10=Sini |last11=Saari |first11=Sina |last12=Kuula |first12=Juho |last13=Hakkarainen |first13=Antti |last14=Tampio |first14=Janne |last15=Saarinen |first15=Tuure |date=2023-01-13 |title=Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study |url=https://www.science.org/doi/10.1126/sciadv.add5163 |journal=Science Advances |language=en |volume=9 |issue=2 |pages=eadd5163 |doi=10.1126/sciadv.add5163 |issn=2375-2548 |pmc=PMC9839336 |pmid=36638183}}</ref><ref>{{Cite journal |last=Yulug |first=Burak |last2=Altay |first2=Ozlem |last3=Li |first3=Xiangyu |last4=Hanoglu |first4=Lutfu |last5=Cankaya |first5=Seyda |last6=Lam |first6=Simon |last7=Velioglu |first7=Halil Aziz |last8=Yang |first8=Hong |last9=Coskun |first9=Ebru |last10=Idil |first10=Ezgi |last11=Nogaylar |first11=Rahim |last12=Ozsimsek |first12=Ahmet |last13=Bayram |first13=Cemil |last14=Bolat |first14=Ismail |last15=Oner |first15=Sena |date=2023-01-26 |title=Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial |url=https://doi.org/10.1186/s40035-023-00336-2 |journal=Translational Neurodegeneration |volume=12 |issue=1 |pages=4 |doi=10.1186/s40035-023-00336-2 |issn=2047-9158 |pmc=PMC9879258 |pmid=36703196}}</ref> |
|||
Thirteen peer-reviewed clinical studies using Niagen have been published in high-tiered biomedical journals, demonstrating an increase in NAD+* [4–13, 21, 22, 24]. These 13 clinical studies include the first-ever clinical NR trial supporting its bioavailability, safety, and efficacy, the pharmacokinetics of NR supplementation in humans, NR’s dose-response effect on blood NAD+ levels, as well as the health benefits of NR supplementation, including improvements in card<ref>{{Cite journal |last=Zeybel |first=Mujdat |last2=Altay |first2=Ozlem |last3=Arif |first3=Muhammad |last4=Li |first4=Xiangyu |last5=Yang |first5=Hong |last6=Fredolini |first6=Claudia |last7=Akyildiz |first7=Murat |last8=Saglam |first8=Burcin |last9=Gonenli |first9=Mehmet Gokhan |last10=Ural |first10=Dilek |last11=Kim |first11=Woonghee |last12=Schwenk |first12=Jochen M |last13=Zhang |first13=Cheng |last14=Shoaie |first14=Saeed |last15=Nielsen |first15=Jens |date=2021-10 |title=Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients |url=https://onlinelibrary.wiley.com/doi/10.15252/msb.202110459 |journal=Molecular Systems Biology |language=en |volume=17 |issue=10 |doi=10.15252/msb.202110459 |issn=1744-4292 |pmc=PMC8724764 |pmid=34694070}}</ref>iovascular health, liver health, body composition, and mitochondrial function. |
|||
Because the safety profile of Niagen is established, validated, and vetted, numerous additional studies in humans are ongoing or have recently completed (as of December 2022). More specifically, an additional 40+ completed or ongoing clinical trials investigating NR only are currently registered on [https://Www.clinicaltrials.gov www.clinicaltrials.gov]. |
|||
= Partnerships and Joint Ventures = |
|||
In June 2022, ChromaDex signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen into mainland China, and in November 2022 the company announced an agreement to launch a joint venture (JV) in the same territory. China’s marketplace can benefit greatly from Tru Niagen, with more than 260 million people over the age of 60. |
|||
A new partnership with MyPharma2Go was formed to conduct cross-border sales of Tru Niagen in Brazil—the first Latin American country to welcome the brand. |
|||
ChromaDex announced a new supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). |
|||
ChromaDex and Nestlé Health Science announced a new Niagen commercial supply agreement and $5 million investment. |
|||
In 2022, ChromaDex launched a Tru Niagen partnership with ShopHQ, a multiplatform interactive television network with live TV programming that reaches roughly 90 million U.S. homes, and influencer Danny Seo, an authoritative voice on living a healthy, natural, good-for-you life. |
|||
In 2022, ChromaDex partnered with Juvenis for cross-border sales of Tru Niagen into South Korea. |
|||
In 2018, ChromaDex announced a Tru Niagen partnership with Watsons, the leading health and beauty retailer in Asia and Europe. |
|||
In 2021, Tru Niagen launched in 3,800 Walmart stores across the United States. |
|||
In 2021, ChromaDex and Health & Happiness (H&H) Group announced a supply agreement for Niagen, in which H&H Group expanded the Swisse® healthy aging product line into the growing NAD+ space with Niagen. |
|||
== Awards == |
|||
NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP) with a [https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nutraingredients.com%2FArticle%2F2022%2F04%2F04%2FDate-for-the-diary-NutraIngredients-Award-winners-of-2022-to-be-revealed-on-4-May&esheet=52721219&newsitemid=20220517005235&lan=en-US&anchor=2022+European+NutraIngredients+Award&index=3&md5=24ba5f3e153cecc42724e07318b51c43 2022 European NutraIngredients Award] in the “Nutrition Research Project” category for developing the science behind patented Niagen. In 2019, NutraIngredients awarded Tru Niagen the Ingredient of the Year award in the Healthy Aging category. |
|||
Tru Niagen is one of Amazon U.S.’s top-selling brands in the vitamin B3 category for boosting NAD<sup>+</sup> levels as of December 2022. |
|||
==References== |
==References== |
Revision as of 01:46, 23 February 2023
Company type | Public |
---|---|
Nasdaq: CDXC Russell 2000 Index component | |
Industry | Dietary supplements, food ingredients, chemical sample analysis |
Founded | 1999 |
Headquarters | Los Angeles, California, United States |
Key people | Rob Fried (CEO) Frank Jaksch (Co-Founder, Executive Chairman) |
Products | Tru Niagen |
Website | www |
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.
In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen and sells directly to consumers as Tru Niagen.[1] ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure.[2] ChromaDex no longer sells pTeroPure.[3]
Elysium Health bought the ingredients in its "Basis" product from ChromaDex.[4] The two firms had an agreement under which Elysium didn't have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the VP of business development from ChromaDex and stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.[5]
References
- ^ Weintraub, Karen. "The Life Extension Death Match". NEO.LIFE.
- ^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.
- ^ Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.
- ^ Zhang, Sarah (July 6, 2016). "The Weird Business Behind a Trendy "Anti-Aging" Pill". Wired.
- ^ Buhr, Sarah (January 16, 2017). "A new lawsuit alleges anti-aging startup Elysium Health hasn't paid its sole supplier". TechCrunch.